Millennium Management’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Millennium Management’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-105,101	Closed	-$1.84M	–	4342
2018 Q1	$1.84M	Buy	105,101 +2,585	+3%	+$47.3K	﹤0.01%	2366
2017 Q4	$1.15M	Sell	102,516 -56,920	-36%	-$594K	﹤0.01%	2612
2017 Q3	$1.7M	Sell	159,436 -29,341	-16%	-$278K	﹤0.01%	2249
2017 Q2	$1.65M	Buy	188,777 +154,849	+456%	+$1.36M	﹤0.01%	2182
2017 Q1	$400K	Sell	33,928 -11,930	-26%	-$145K	﹤0.01%	2916
2016 Q4	$601K	Buy	+45,858	New	+$614K	﹤0.01%	2582
2015 Q2	–	Sell	-8,984	Closed	-$283K	–	4024
2015 Q1	$283K	Buy	+8,984	New	+$243K	﹤0.01%	3079

Other funds holding CBMG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Millennium Management's CBMG Position: Q2 2018 in Review

Millennium Management sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q2 2018, closing a stake of 105,101 shares — an estimated $1.84M sold.

Millennium Management first reported a position in CBMG in Q1 2015 and held it in 7 quarters. The position peaked at $1.84M in Q1 2018. 34 funds tracked by Wall St. Rank hold CBMG as of Q2 2018.

Millennium Management reported no remaining Cellular Biomedicine Group, Inc. position as of Q2 2018 after selling out during the quarter.
Millennium Management sold 105,101 Cellular Biomedicine Group, Inc. shares in Q2 2018, an estimated $1.84M.
Millennium Management first reported a position in Cellular Biomedicine Group, Inc. in Q1 2015 and held it in 7 quarters.
Millennium Management's Cellular Biomedicine Group, Inc. position peaked at $1.84M in Q1 2018.
34 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q2 2018.

Based on Millennium Management's 13F filing for Q2 2018, filed 14 Aug 2018.